JPWO2021016602A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021016602A5
JPWO2021016602A5 JP2022504572A JP2022504572A JPWO2021016602A5 JP WO2021016602 A5 JPWO2021016602 A5 JP WO2021016602A5 JP 2022504572 A JP2022504572 A JP 2022504572A JP 2022504572 A JP2022504572 A JP 2022504572A JP WO2021016602 A5 JPWO2021016602 A5 JP WO2021016602A5
Authority
JP
Japan
Prior art keywords
seq
composition
sequence
group
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022504572A
Other languages
Japanese (ja)
Other versions
JP2022542361A (en
Publication date
Priority claimed from US16/719,744 external-priority patent/US10954572B2/en
Application filed filed Critical
Publication of JP2022542361A publication Critical patent/JP2022542361A/en
Publication of JPWO2021016602A5 publication Critical patent/JPWO2021016602A5/ja
Pending legal-status Critical Current

Links

Description

一部の実施形態では、本発明は、配列番号１～７６に対して、少なくとも９０％、少なくとも９５％、少なくとも９６％、少なくとも９７％、少なくとも９８％、少なくとも９９％％、少なくとも９９．１％、少なくとも９９．２％、少なくとも９９．３％、少なくとも９９．４％、少なくとも９９．５％、少なくとも９９．６％、少なくとも９９．７％、少なくとも９９．８％、または少なくとも９９．９％が同一である核酸配列、及び、それらの核酸を使用して、試験試料中のナイセリア・ゴノレアを検出する方法を提供する。
[本発明1001]
セット－1～セット－15からなる群から選択される配列特異的プライマーセットを含む、組成物。
[本発明1002]
前記配列特異的プライマーセットが、セット－5、セット－11、セット－13、セット－14、及びセット－15からなる群から選択される、本発明1001の組成物。
[本発明1003]
前記配列特異的プライマーセットがセット－15である、本発明1002の方法。
[本発明1004]
プローブをさらに含む、本発明1001の組成物。
[本発明1005]
前記プローブが標識を含む、本発明1004の組成物。
[本発明1006]
前記プローブが、標識されたポリヌクレオチドである、本発明1005の組成物。
[本発明1007]
前記標識されたポリヌクレオチドが、配列番号73のヌクレオチド6～22、配列番号74のヌクレオチド5～24、配列番号75のヌクレオチド3～21、及び配列番号76のヌクレオチド3～24からなる群から選択される配列を含む、本発明1006の組成物。
[本発明1008]
前記標識されたポリヌクレオチドが、配列番号73～配列番号76からなる群から選択される配列を含む、本発明1006の組成物。
[本発明1009]
前記標識がフルオロフォアである、本発明1006の組成物。
[本発明1010]
前記フルオロフォアが、前記ポリヌクレオチドの末端に共有結合している、本発明1009の組成物。
[本発明1011]
前記プローブが、フルオロフォアとクエンチャーとポリヌクレオチドとを含む分子ビーコンである、本発明1004の組成物。
[本発明1012]
前記分子ビーコンが、配列番号73～配列番号76からなる群から選択される配列を含む、本発明1011の組成物。
[本発明1013]
ポリヌクレオチド配列が配列番号75からなる、本発明1012の組成物。
[本発明1014]
以下を含む、試験試料中のナイセリア・ゴノレア（Ｎｅｉｓｓｅｒｉａ ｇｏｎｏｒｒｈｏｅａｅ）を検出する方法：
前記試験試料から核酸を抽出すること；
ステップ（ａ）で抽出した核酸を、鎖置換ＤＮＡポリメラーゼと配列特異的プライマーセットとを含む反応混合物と反応させることによって、標的配列を増幅することであって、前記配列特異的プライマーセットが、セット－1～セット－15からなる群から選択される、前記増幅すること；及び
ステップ（ｂ）の増幅産物の有無を検出することであって、前記増幅産物の存在が、前記試験試料中のナイセリア・ゴノレアの存在を示す、前記検出すること。
[本発明1015]
増幅ステップが15分未満の間行われる、本発明1014の方法。
[本発明1016]
増幅ステップが10分未満の間行われる、本発明1014の方法。
[本発明1017]
前記反応混合物が逆転写酵素をさらに含む、本発明1014の方法。
[本発明1018]
前記増幅産物の有無を検出することが、前記増幅産物を、標識に結合しているポリヌクレオチドを含むプローブとハイブリダイズさせることを含む、本発明1014の方法。
[本発明1019]
標識された前記ポリヌクレオチドが、配列番号73のヌクレオチド6～22、配列番号74のヌクレオチド5～24、配列番号75のヌクレオチド3～21、及び配列番号76のヌクレオチド3～24からなる群から選択される配列を含む、本発明1018の方法。
[本発明1020]
標識された前記ポリヌクレオチドが、配列番号73～配列番号76からなる群から選択される配列を含む、本発明1019の方法。
[本発明1021]
前記配列特異的プライマーセットが、セット－5、セット－11、セット－13、セット－14、及びセット－15からなる群から選択される、本発明1014の方法。
[本発明1022]
前記配列特異的プライマーセットがセット－15である、本発明1021の方法。
[本発明1023]
ナイセリア・ゴノレアが、≦100ＣＦＵ／ｍＬの濃度で前記試験試料に存在する、本発明1014の方法。
[本発明1024]
ナイセリア・ゴノレアが、≦10ＣＦＵ／ｍＬの濃度で試験試料に存在する、本発明1023の方法。
[本発明1025]
ナイセリア・ゴノレアが、≦10ＣＦＵ／ｍＬの濃度で前記試験試料に存在し、かつ、増幅反応が15分未満の間行われる、本発明1024の方法。
[本発明1026]
本発明1001の組成物を含む、キット。
[本発明1027]
鎖置換ポリメラーゼをさらに含む、本発明1026のキット。
[本発明1028]
逆転写酵素をさらに含む、本発明1027のキット。
In some embodiments, the present invention provides at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1% , at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% Nucleic acid sequences that are identical and methods of using those nucleic acids to detect Neisseria gonorrhoeae in test samples are provided.
[Invention 1001]
A composition comprising a sequence-specific primer set selected from the group consisting of set-1 through set-15.
[Invention 1002]
1001. The composition of the present invention 1001, wherein said sequence-specific primer set is selected from the group consisting of set-5, set-11, set-13, set-14, and set-15.
[Invention 1003]
1002. The method of the invention 1002, wherein said sequence-specific primer set is set-15.
[Invention 1004]
The composition of the invention 1001, further comprising a probe.
[Invention 1005]
The composition of invention 1004, wherein said probe comprises a label.
[Invention 1006]
The composition of invention 1005, wherein said probe is a labeled polynucleotide.
[Invention 1007]
said labeled polynucleotide is selected from the group consisting of nucleotides 6-22 of SEQ ID NO:73, nucleotides 5-24 of SEQ ID NO:74, nucleotides 3-21 of SEQ ID NO:75, and nucleotides 3-24 of SEQ ID NO:76. The composition of the invention 1006, comprising the sequence
[Invention 1008]
1006. The composition of the invention 1006, wherein said labeled polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:73-SEQ ID NO:76.
[Invention 1009]
The composition of invention 1006, wherein said label is a fluorophore.
[Invention 1010]
1009. The composition of invention 1009, wherein said fluorophore is covalently attached to the terminus of said polynucleotide.
[Invention 1011]
The composition of invention 1004, wherein said probe is a molecular beacon comprising a fluorophore, a quencher and a polynucleotide.
[Invention 1012]
1011. The composition of the invention 1011, wherein said molecular beacon comprises a sequence selected from the group consisting of SEQ ID NO:73-SEQ ID NO:76.
[Invention 1013]
1012. The composition of the invention 1012, wherein the polynucleotide sequence consists of SEQ ID NO:75.
[Invention 1014]
A method of detecting Neisseria gonorrhoeae in a test sample comprising:
extracting nucleic acids from the test sample;
Amplifying a target sequence by reacting the nucleic acid extracted in step (a) with a reaction mixture comprising a strand-displacing DNA polymerase and a sequence-specific primer set, wherein the sequence-specific primer set said amplifying selected from the group consisting of -1 to set-15; and
detecting the presence or absence of the amplification product of step (b), wherein the presence of said amplification product indicates the presence of Neisseria gonorrhoeae in said test sample.
[Invention 1015]
1014. The method of the invention 1014, wherein the amplification step is performed for less than 15 minutes.
[Invention 1016]
1014. The method of the invention 1014, wherein the amplification step is performed for less than 10 minutes.
[Invention 1017]
1015. The method of invention 1014, wherein said reaction mixture further comprises reverse transcriptase.
[Invention 1018]
1015. The method of invention 1014, wherein detecting the presence or absence of said amplification product comprises hybridizing said amplification product with a probe comprising a polynucleotide bound to a label.
[Invention 1019]
said labeled polynucleotide is selected from the group consisting of nucleotides 6-22 of SEQ ID NO:73, nucleotides 5-24 of SEQ ID NO:74, nucleotides 3-21 of SEQ ID NO:75, and nucleotides 3-24 of SEQ ID NO:76. The method of the invention 1018, comprising the sequence
[Invention 1020]
The method of invention 1019, wherein said labeled polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:73-SEQ ID NO:76.
[Invention 1021]
1015. The method of the invention 1014, wherein said sequence-specific primer set is selected from the group consisting of Set-5, Set-11, Set-13, Set-14, and Set-15.
[Invention 1022]
1021. The method of the invention 1021, wherein said sequence-specific primer set is set-15.
[Invention 1023]
1015. The method of invention 1014, wherein Neisseria gonorrhoeae is present in said test sample at a concentration of < 100 CFU/mL.
[Invention 1024]
1023. The method of invention 1023, wherein Neisseria gonorrhoeae is present in the test sample at a concentration of ≦10 CFU/mL.
[Invention 1025]
1024. The method of the invention 1024, wherein Neisseria gonorrhoeae is present in said test sample at a concentration of ≦10 CFU/mL and the amplification reaction is conducted for less than 15 minutes.
[Invention 1026]
A kit comprising the composition of the invention 1001.
[Invention 1027]
The kit of the invention 1026, further comprising a strand displacement polymerase.
[Invention 1028]
The kit of the invention 1027, further comprising reverse transcriptase.

Claims (28)

セット－１５及びセット－１～セット－１４からなる群から選択される配列特異的プライマーセットを含む、組成物。 A composition comprising a sequence-specific primer set selected from the group consisting of Set -15 and Set-1 through Set-14 . 前記配列特異的プライマーセットが、セット－１５、セット－５、セット－１１、セット－１３、及びセット－１４からなる群から選択される、請求項１に記載の組成物。 2. The composition of claim 1, wherein said sequence-specific primer set is selected from the group consisting of Set-15, Set-5, Set-11, Set-13, and Set- 14 . 前記配列特異的プライマーセットがセット－１５である、請求項２に記載の組成物。 3. The composition of claim 2, wherein said sequence-specific primer set is set-15. プローブをさらに含む、請求項１に記載の組成物。 2. The composition of claim 1, further comprising a probe. 前記プローブが標識を含む、請求項４に記載の組成物。 5. The composition of Claim 4, wherein said probe comprises a label. 前記プローブが、標識されたポリヌクレオチドである、請求項５に記載の組成物。 6. The composition of claim 5, wherein said probe is a labeled polynucleotide. 前記標識されたポリヌクレオチドが、配列番号７５のヌクレオチド３～２１、配列番号７３のヌクレオチド６～２２、配列番号７４のヌクレオチド５～２４、及び配列番号７６のヌクレオチド３～２４からなる群から選択される配列を含む、請求項６に記載の組成物。 wherein said labeled polynucleotide is selected from the group consisting of nucleotides 3-21 of SEQ ID NO:75, nucleotides 6-22 of SEQ ID NO:73, nucleotides 5-24 of SEQ ID NO:74 , and nucleotides 3-24 of SEQ ID NO:76. 7. The composition of claim 6, comprising the sequence 前記標識されたポリヌクレオチドが、配列番号７５、配列番号７３、配列番号７４、及び配列番号７６からなる群から選択される配列を含む、請求項６に記載の組成物。 7. The composition of claim 6, wherein said labeled polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:75, SEQ ID NO:73 , SEQ ID NO:74, and SEQ ID NO:76. 前記標識がフルオロフォアである、請求項６に記載の組成物。 7. The composition of claim 6, wherein said label is a fluorophore. 前記フルオロフォアが、前記ポリヌクレオチドの末端に共有結合している、請求項９に記載の組成物。 10. The composition of claim 9, wherein said fluorophore is covalently attached to the terminus of said polynucleotide. 前記プローブが、フルオロフォアとクエンチャーとポリヌクレオチドとを含む分子ビーコンである、請求項４に記載の組成物。 5. The composition of claim 4, wherein said probe is a molecular beacon comprising a fluorophore, a quencher and a polynucleotide. 前記分子ビーコンが、配列番号７５、配列番号７３、配列番号７４、及び配列番号７６からなる群から選択される配列を含む、請求項１１に記載の組成物。 12. The composition of claim 11, wherein said molecular beacon comprises a sequence selected from the group consisting of SEQ ID NO:75, SEQ ID NO:73 , SEQ ID NO:74, and SEQ ID NO:76. ポリヌクレオチド配列が配列番号７５からなる、請求項１２に記載の組成物。 13. The composition of claim 12, wherein the polynucleotide sequence consists of SEQ ID NO:75. 以下を含む、試験試料中のナイセリア・ゴノレア（Ｎｅｉｓｓｅｒｉａ ｇｏｎｏｒｒｈｏｅａｅ）を検出する方法：
（ａ）前記試験試料から核酸を抽出すること；
（ｂ）ステップ（ａ）で抽出した核酸を、鎖置換ＤＮＡポリメラーゼと配列特異的プライマーセットとを含む反応混合物と反応させることによって、標的配列を増幅することであって、前記配列特異的プライマーセットが、セット－１５及びセット－１～セット－１４からなる群から選択される、前記増幅すること；及び
（ｃ）ステップ（ｂ）の増幅産物の有無を検出することであって、前記増幅産物の存在が、前記試験試料中のナイセリア・ゴノレアの存在を示す、前記検出すること。 A method of detecting Neisseria gonorrhoeae in a test sample comprising:
(a) extracting nucleic acids from said test sample;
(b) amplifying the target sequence by reacting the nucleic acid extracted in step (a) with a reaction mixture comprising a strand-displacing DNA polymerase and a sequence-specific primer set, said sequence-specific primer set; is selected from the group consisting of Set -15 and Set-1 through Set-14 ; and
(c) detecting the presence or absence of the amplification product of step (b), wherein the presence of said amplification product indicates the presence of Neisseria gonorrhoeae in said test sample; 増幅ステップが１５分未満の間行われる、請求項１４に記載の方法。 15. The method of claim 14, wherein the amplifying step is performed for less than 15 minutes. 増幅ステップが１０分未満の間行われる、請求項１４に記載の方法。 15. The method of claim 14, wherein the amplifying step is performed for less than 10 minutes. 前記反応混合物が逆転写酵素をさらに含む、請求項１４に記載の方法。 15. The method of claim 14, wherein said reaction mixture further comprises reverse transcriptase. 前記増幅産物の有無を検出することが、前記増幅産物を、標識に結合しているポリヌクレオチドを含むプローブとハイブリダイズさせることを含む、請求項１４に記載の方法。 15. The method of claim 14, wherein detecting the presence or absence of the amplification product comprises hybridizing the amplification product with a probe comprising a polynucleotide bound to a label. 標識された前記ポリヌクレオチドが、配列番号７５のヌクレオチド３～２１、配列番号７３のヌクレオチド６～２２、配列番号７４のヌクレオチド５～２４、及び配列番号７６のヌクレオチド３～２４からなる群から選択される配列を含む、請求項１８に記載の方法。 said labeled polynucleotide is selected from the group consisting of nucleotides 3-21 of SEQ ID NO:75, nucleotides 6-22 of SEQ ID NO:73, nucleotides 5-24 of SEQ ID NO:74 , and nucleotides 3-24 of SEQ ID NO:76. 19. The method of claim 18, comprising the sequence 標識された前記ポリヌクレオチドが、配列番号７５、配列番号７３、配列番号７４、及び配列番号７６からなる群から選択される配列を含む、請求項１９に記載の方法。 20. The method of claim 19, wherein said labeled polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:75, SEQ ID NO:73 , SEQ ID NO:74, and SEQ ID NO:76. 前記配列特異的プライマーセットが、セット－１５、セット－５、セット－１１、セット－１３、及びセット－１４からなる群から選択される、請求項１４に記載の方法。 15. The method of claim 14, wherein said sequence-specific primer set is selected from the group consisting of Set-15, Set-5, Set-11, Set-13, and Set- 14 . 前記配列特異的プライマーセットがセット－１５である、請求項２１に記載の方法。 22. The method of claim 21, wherein said sequence-specific primer set is set-15. ナイセリア・ゴノレアが、≦１００ＣＦＵ／ｍＬの濃度で前記試験試料に存在する、請求項１４に記載の方法。 15. The method of claim 14, wherein Neisseria gonorrhoeae is present in the test sample at a concentration of <100 CFU/mL. ナイセリア・ゴノレアが、≦１０ＣＦＵ／ｍＬの濃度で試験試料に存在する、請求項２３記載の方法。 24. The method of claim 23, wherein Neisseria gonorrhoeae is present in the test sample at a concentration < 10 CFU/mL. ナイセリア・ゴノレアが、≦１０ＣＦＵ／ｍＬの濃度で前記試験試料に存在し、かつ、増幅反応が１５分未満の間行われる、請求項２４に記載の方法。 25. The method of claim 24, wherein Neisseria gonorrhoeae is present in the test sample at a concentration < 10 CFU/mL and the amplification reaction is performed for less than 15 minutes. 請求項１に記載の組成物を含む、キット。 A kit comprising the composition of claim 1. 鎖置換ポリメラーゼをさらに含む、請求項２６に記載のキット。 27. The kit of claim 26, further comprising a strand displacement polymerase. 逆転写酵素をさらに含む、請求項２７に記載のキット。 28. The kit of claim 27, further comprising reverse transcriptase.
JP2022504572A 2019-07-25 2020-07-24 Polynucleotides for amplification and detection of Neisseria gonorrhoeae Pending JP2022542361A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962878639P 2019-07-25 2019-07-25
US62/878,639 2019-07-25
US201916523609A 2019-07-26 2019-07-26
US16/523,609 2019-07-26
US16/719,744 2019-12-18
US16/719,744 US10954572B2 (en) 2019-07-25 2019-12-18 Polynucleotides for the amplification and detection of Neisseria gonorrhoeae
PCT/US2020/043620 WO2021016602A1 (en) 2019-07-25 2020-07-24 Polynucleotides for the amplification and detection of neisseria gonorrhoeae

Publications (2)

Publication Number Publication Date
JP2022542361A JP2022542361A (en) 2022-10-03
JPWO2021016602A5 true JPWO2021016602A5 (en) 2023-07-28

Family

ID=74190742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022504572A Pending JP2022542361A (en) 2019-07-25 2020-07-24 Polynucleotides for amplification and detection of Neisseria gonorrhoeae

Country Status (14)

Country Link
US (1) US10954572B2 (en)
EP (1) EP4004014A4 (en)
JP (1) JP2022542361A (en)
KR (1) KR20220044760A (en)
CN (1) CN114502747A (en)
AU (1) AU2020315931A1 (en)
BR (1) BR112022001038A2 (en)
CA (1) CA3147244A1 (en)
CL (1) CL2022000126A1 (en)
CO (1) CO2022001223A2 (en)
IL (1) IL289461A (en)
JO (1) JOP20220004A1 (en)
MX (1) MX2022000907A (en)
WO (1) WO2021016602A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11891662B2 (en) 2019-12-02 2024-02-06 Talis Biomedical Corporation Polynucleotides for amplification and detection of human beta actin
PL437280A1 (en) * 2021-03-12 2022-09-19 Genomtec Spółka Akcyjna Amplification primer set, method for detecting a sexually transmitted bacterial infection, and infection detection kit
WO2023023601A1 (en) * 2021-08-18 2023-02-23 Talis Biomedical Corporation Polynucleotides for the amplification and detection of influenza a

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234809A (en) 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
US5155018A (en) 1991-07-10 1992-10-13 Hahnemann University Process and kit for isolating and purifying RNA from biological sources
DE4321904B4 (en) 1993-07-01 2013-05-16 Qiagen Gmbh Method for chromatographic purification and separation of nucleic acid mixtures
US5514551A (en) 1994-10-14 1996-05-07 Gen-Probe Incorporated Compositions for the detection of Chlamydia trachomatis
ES2230631T3 (en) 1997-03-20 2005-05-01 F. Hoffmann-La Roche Ag MODIFIED PRIMERS.
US7572902B2 (en) 1997-12-09 2009-08-11 Monsanto Technology Llc Nucleic acid molecules seq id No. 16372 and other molecules associated with plants
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
JP4410268B2 (en) 2007-03-28 2010-02-03 株式会社東芝 Nucleic acid primer set and nucleic acid probe for detecting the genotype of methylenetetrahydrofolate reductase (MTHFR)
WO2008127921A2 (en) 2007-04-13 2008-10-23 Abbott Laboratories Primer and probe sequences for detecting chlamydia trachomatis
EP2218780B1 (en) 2007-10-19 2013-07-24 Eiken Kagaku Kabushiki Kaisha Nucleic acid amplification method, and reagent and reagent kit for use in the method
CN101831488A (en) 2009-03-11 2010-09-15 孙星江 Method for quickly detecting gonorrhea Neisseria by utilizing loop-mediated isothermal amplification technology
GB0922097D0 (en) 2009-12-17 2010-02-03 Atlas Genetics Ltd Microbial assay
CN101886122B (en) 2010-05-10 2012-10-17 珠海市银科医学工程有限公司 Method for detecting chlamydia pneumoniae by loop-mediated isothermal amplification and detection kit
EP2388312A1 (en) 2010-05-17 2011-11-23 Curetis AG Universally applicable lysis buffer and processing methods for the lysis of bodily samples
JP2012085605A (en) 2010-10-22 2012-05-10 Sony Corp Nucleic acid amplification reaction device, substrate used for nucleic acid amplification reaction device, and nucleic acid amplification reaction method
WO2012054588A2 (en) 2010-10-22 2012-04-26 T2 Biosystems, Inc. Conduit-containing devices and methods for analyte processing and detection
WO2013009340A1 (en) 2011-07-11 2013-01-17 Program For Appropriate Technology In Health Methods and compositions for chlamydia trachomatis diagnostic testing
ES2755934T3 (en) 2011-10-31 2020-04-24 Eiken Chemical Method for detecting target nucleic acid
US9809845B2 (en) 2012-08-06 2017-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and reagents for amplifying nucleic acids
US20140114215A1 (en) 2012-10-20 2014-04-24 Medtronic Ardian Luxembourg S.A.R.L. Methods for Renal Neuromodulation and Associated Systems and Devices
CA2888720A1 (en) 2012-10-22 2014-05-01 Bayer Cropscience Nv Methods, compositions and devices for amplification of nucleic acids
US10329629B2 (en) 2013-07-26 2019-06-25 Cepheid Methods of detecting chlamydia and gonorrhea and of screening for infection/inflammation based on genomic copy number
WO2015058008A2 (en) 2013-10-18 2015-04-23 California Institute Of Technology Enhanced nucleic acid identification and detection
GB201319180D0 (en) * 2013-10-30 2013-12-11 Mast Group Ltd Nucleic acid probe
US10364458B2 (en) 2014-07-16 2019-07-30 Tangen Biosciences, Inc. Isothermal methods for amplifying nucleic acid samples
JP7055020B2 (en) 2014-11-05 2022-04-15 カリフォルニア インスティテュート オブ テクノロジー Microfluidic measurement of biological response to drugs
US10227661B2 (en) 2014-11-21 2019-03-12 GeneWeave Biosciences, Inc. Sequence-specific detection and phenotype determination
WO2016105508A2 (en) 2014-12-23 2016-06-30 California Institute Of Technology Devices and methods for autonomous measurements
US9657353B2 (en) 2015-06-26 2017-05-23 Great Basin Scientific, Inc. Specific detection of organisms derived from a sample
AU2017261283B2 (en) 2016-05-04 2023-02-09 Children's Hospital & Research Center At Oakland Rapid extraction of nucleic acids from clinical samples for downstream applications
US20190284617A1 (en) 2016-11-10 2019-09-19 Talis Biomedical Corporation Polynucleotides for the amplification and detection of chlamydia trachomatis
EP3538538A4 (en) 2016-11-10 2020-11-04 Talis Biomedical Corporation Polynucleotides for the amplification and detection of neisseria gonorrhoeae
US20210254139A1 (en) 2016-11-10 2021-08-19 Talis Biomedical Corporation Probe detection of loop-mediated amplification products
CN107099618A (en) 2017-05-03 2017-08-29 上海速创诊断产品有限公司 A kind of LAMP primer composition thing and its related application for being used to detect urogenital tract pathogenic microorganisms
US10450616B1 (en) 2018-05-09 2019-10-22 Talis Biomedical Corporation Polynucleotides for the amplification and detection of Chlamydia trachomatis

Similar Documents

Publication Publication Date Title
US20210388430A1 (en) Compositions of toehold primer duplexes and methods of use
CN107109489B (en) Nanopore RNA characterization method
JP4903725B2 (en) Method using bispecific oligonucleotide and bispecific oligonucleotide
CN107257862B (en) Sequencing from multiple primers to increase data rate and density
JPH1169987A (en) Amplification and detection of hiv-i and/or hiv-2
RU2729983C2 (en) Dna amplification method based on chain insertion
WO2014106076A2 (en) Universal sanger sequencing from next-gen sequencing amplicons
JP2015516814A (en) Enrichment and sequencing of targeted DNA
WO1995003412A2 (en) Nucleotide fragment of mycobacterial ribosomal rna 23s, probes and primers derived therefrom, reagent and method for detecting said fragment
JPH08507198A (en) Single nucleotide primer extension method for the detection of specific alleles and a kit therefor
EP3976899A1 (en) Flexible and high-throughput sequencing of targeted genomic regions
FR2694768A1 (en) Oligonucleotide sequences for the specific detection of mollicutes by amplification of conserved genes.
GB2549799A (en) A multiplex assay for the sensitive and specific detection and differentiation of Clostridium difficile
JPWO2021016602A5 (en)
TW202227640A (en) Oligonucleotides for detecting lactobacillus and method for detecting lactobacillus by using same
JP2002000275A (en) New method for quantitatively analyzing polymorphism
FR2733755A1 (en) NUCLEOTIDE FRAGMENT OF 16S CORYNEBACTERIA RIBOSOME RNA, DERIVED PROBES AND PRIMERS, REAGENT AND DETECTION METHOD
FR2933410A1 (en) NEW DETECTION PROBE
US7585626B1 (en) Methods for nucleic acid amplification
CN116042928B (en) Primer group for amplifying and detecting nucleic acid sequence of digestive tract virus
KR101651212B1 (en) DNA Aptamer Capable of Specifically Binding to Surface of Living Cell of Shigella sonnei and Uses Thereof
US20220136042A1 (en) Improved nucleic acid target enrichment and related methods
EP2094865B1 (en) Method for molecular identification and genotyping of bacteria of the mycobacterium tuberculosis complex
RU2021134298A (en) Method for obtaining molecular markers for personal identification based on autosomal STR markers by multiplex amplification
Singer et al. Artificial nucleic acid probes and their applications in clinical microbiology